Please assess the completion status of the following clinical trial:

Trial Title: ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Illness severity criteria: At enrolment subjects must meet inclusion criteria #1 through #3 listed below to be eligible to enter the clinical investigation:~1. Subjects must have suspected severe infection of abdominal or urogenital origin for which the subject is receiving intravenous antimicrobial therapy as the main reason for organ support~2. Subjects, males or females, must be 18 years or older.~3. Subjects or legally acceptable representatives, as appropriate, are willing and able to provide signed informed consent.~   Treatment criteria: Prior to randomization, subjects must meet all inclusion criteria (#4 through #7) listed below to be assigned to a treatment group:~4. Appropriate vascular access must have been obtained.~5. Subjects must have received ≥ 30 mL/kg of intravenous fluid within the six (6) hours prior to randomization.~6. Subjects must have plasma/serum lactate \>2 mmol/L despite adequate resuscitation AND a continuous requirement for vasopressor support~7. Subjects must be able to initiate the clinical investigation intervention within 12 hours of fulfilment of the illness severity criteria.~Exclusion Criteria:~1. Subjects who meet any of the exclusion criteria listed below will NOT be permitted to enter the clinical investigation: Sepsis-induced organ dysfunction for longer than 12 hours prior to the time-point for achieving Illness severity criteria fulfilled~2. Vasopressor therapy (at any dose) for longer than 12 hours (not included the time spent in the operation theatre) prior to the start of treatment with the investigational device.~3. Pre-existing uncorrectable medical condition as:~   * Poorly controlled neoplasms or hematologic disease (i.e. indication of disseminated cancer outside the suspected primary tumour and hematologic disease not in remission,~  * End-stage cardiac disease,~  * Cardiac arrest requiring cardiopulmonary resuscitation or with pulseless electrical activity or asystole within the past 7 days~  * End-stage lung disease~  * End-stage liver disease~  * HIV/AIDS with known end-stage processes~  * Other uncorrectable medical condition(s) deemed by the Clinical Investigator to hinder the subject to adhere to the fulfilment of the activities described in the Clinical Investigation Plan.~4. Extreme illness, i.e. subjects is moribund and death is perceived to be imminent (within 24 hours).~5. Recent or current participation (≤ 30 days) in another interventional sepsis trial.~6. Recent or current treatment (≤ 30 days) with an adsorption product, including Alteco® LPS Adsorber.~7. Treatment with an investigational medicinal product for any indication within the last 30 days before enrolment in the clinical investigation.~8. Pregnancy.~9. Contraindications to the use heparin or protamine~10. Other abdominal inflammatory conditions~11. Perforation of hollow organ linked to trauma within 48 hours before enrolment in the clinical investigation.~12. Laparotomy reveals isolated gastric ulcer.~13. Subjects and/or their immediate family are directly affiliated to investigative site personnel in this clinical investigation. (Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alteco LPS Adsorber (Type: ACTIVE_COMPARATOR): Hemoperfusion and Standard therapy
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.

Based on this trial design, predict the completion outcome and termination type (if applicable).